SCHEMBL19847358

SCHEMBL19847358

CCC(CC)C[C@@H](CC)NS(=O)(=O)c1ccccc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.53
ALDH1A1 P00352 3/20 0.50
CYP1A2 P05177 1/20 0.50
CYP2C9 P11712 1/20 0.50
CYP2C19 P33261 1/20 0.50
CA2 P00918 4/20 0.44
CA1 P00915 3/20 0.44
CA7 P43166 2/20 0.44
MMP2 P08253 2/20 0.44
CA9 Q16790 2/20 0.44
CA12 O43570 1/20 0.44
CA14 Q9ULX7 1/20 0.44
KDM4E B2RXH2 2/20 0.43
PIN1 Q13526 1/20 0.43
NR3C1 P04150 1/20 0.43
PGR P06401 1/20 0.43
NR3C2 P08235 1/20 0.43
LMNA P02545 1/20 0.43
GBA1 P04062 1/20 0.41
PSIP1 O75475 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27388797 0.84 SMN1; SMN2 (0.54) SMN1; SMN2ALDH1A1CYP1A2CYP2C9CYP2C19
SCHEMBL5261326 0.81 SMN1; SMN2 (0.68) SMN1; SMN2ALDH1A1CYP1A2CYP2C9CYP2C19
SCHEMBL6368625 0.81 SMN1; SMN2 (0.54) SMN1; SMN2ALDH1A1CYP1A2CYP2C9CYP2C19
SCHEMBL25525586 0.79 SMN1; SMN2 (0.59) SMN1; SMN2ALDH1A1CYP1A2CYP2C9CYP2C19
SCHEMBL9577105 0.78 SMN1; SMN2 (0.54) SMN1; SMN2ALDH1A1CYP1A2CYP2C9CYP2C19
SCHEMBL14281899 0.78 SMN1; SMN2 (0.58) SMN1; SMN2ALDH1A1CYP1A2CYP2C9CYP2C19
SCHEMBL27821808 0.77 SMN1; SMN2 (0.72) SMN1; SMN2ALDH1A1CYP1A2CYP2C9CYP2C19
SCHEMBL15341681 0.76 SMN1; SMN2 (0.53) SMN1; SMN2ALDH1A1CYP1A2CYP2C9CYP2C19
SCHEMBL3971671 0.75 SMN1; SMN2 (0.74) SMN1; SMN2ALDH1A1CYP1A2CYP2C9CYP2C19
SCHEMBL9765289 0.74 NR3C1 (0.62) SMN1; SMN2CA2CA7MMP2PIN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3116860-B1 SULFONAMIDES DERIVED FROM TRICYCLYL-2-AMINOCYCLOALKANOLS AS ANTICANCER AGENTS ICAHN SCHOOL MED MOUNT SINAI (US) 2018-02-07 EP disclosed